DBV Technologies (DBVT) Shareholder's Equity Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,068.97% |
| Dec 31, 2025 | 516.06% |
| Sep 30, 2025 | -2.18% |
| Jun 30, 2025 | 9.01% |
| Mar 31, 2025 | -97.40% |
| Dec 31, 2024 | -80.45% |
| Sep 30, 2024 | -62.47% |
| Jun 30, 2024 | -51.84% |
| Mar 31, 2024 | -37.66% |
| Dec 31, 2023 | -27.91% |
| Sep 30, 2023 | -32.10% |
| Jun 30, 2023 | -32.80% |
| Mar 31, 2023 | 118.24% |
| Dec 31, 2022 | 95.88% |
| Sep 30, 2022 | 81.41% |
| Jun 30, 2022 | 70.90% |
| Mar 31, 2022 | -51.49% |
| Dec 31, 2021 | -51.69% |
| Sep 30, 2021 | -49.85% |
| Jun 30, 2021 | -43.19% |
| Mar 31, 2021 | -43.54% |
| Dec 31, 2020 | 8.21% |
| Sep 30, 2020 | 144.04% |
| Jun 30, 2020 | 92.59% |
| Dec 31, 2019 | 37.18% |
| Jun 30, 2019 | -46.55% |
| Dec 31, 2018 | -9.50% |
| Jun 30, 2018 | 16.04% |
| Dec 31, 2017 | -41.66% |
| Jun 30, 2017 | -35.78% |
| Dec 31, 2016 | -25.73% |
| Jun 30, 2016 | 181.14% |
| Dec 31, 2015 | 144.67% |